RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172

Benzinga · 05/07 17:19
RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $182 to $172.